Alpha Teknova Inc (TKNO) Stock AnalysisTKNOAlpha Teknova Inc

Alpha Teknova, Inc. is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The Company offers three primary product types: pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It offers a range of standard and specialty pre-poured media plates for a variety of applications including bacteria, fungi, and nematode growth. Its two primary product categories include Lab Essentials and Clinical Solutions. Its core Lab Essentials products consist of commonly used catalog solutions and customer-specified formulations. Its Clinical Solutions products are custom products used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Alpha Teknova is a good buy right now due to its recent record revenue growth of 18% in Q2 2026, reaching over $12 million, and a gross margin improvement to 37.73%. The main risk is its current negative net income of -3.17 million for Q2 2026, but the company's diversified customer base and strong revenue outlook suggest a positive trajectory.